KOZARICH JOHN W 4

What Happened
John W. Kozarich, a director of Ligand Pharmaceuticals, was granted a total of 3,774 restricted stock units (RSUs) on June 5, 2026. The filing reports two grant entries: 836 RSUs (acquired) and 2,938 RSUs recorded as a derivative award; both show $0.00 per share (no cash exchanged). These RSUs are contingent rights to receive shares upon vesting.

Key Details

• Transaction date: 2026-06-05; Filing date: 2026-06-09 (filed on time).
• Grants: 836 RSUs (A) and 2,938 RSUs (A, derivative) — total 3,774 RSUs; reported price $0.00.
• Vesting: Grants fully vest on the earlier of (A) the next annual meeting of stockholders after the grant date or (B) the first anniversary of the grant (per footnotes).
• Shares owned after transaction: Not specified in the filing.
• Footnotes: F1/F2 confirm these are RSUs (each convertible to one share upon vesting) and were approved by the Board at the annual meeting.

Context
This is a routine equity award to a director as part of compensation and does not represent an open-market purchase or sale. RSUs are contingent (derivative) rights and will convert into actual shares only if and when they vest; such awards do not by themselves signal an immediate buying or selling intent.